Betalin Therapeutics
Tissue Engineering for Insulin Therapy Alternative
Company Overview
Snapshot
Founded in July 2015 by Shuki Joshua Hershcovich and Shay Hershcovich, Betalin Therapeutics operates with 1–10 employees. The company has raised a total of $11.06 million across 6 funding rounds from 3 investors.
Business overview
Betalin Therapeutics is a Health Tech & Life Sciences company focused on developing an alternative to insulin injections and glucose testing for diabetes patients. The company's core product is its proprietary Engineered Micro Pancreas (EMP) technology, which facilitates the creation of connective tissue to enable the body's beta cells to function correctly and produce adequate insulin. Betalin Therapeutics serves global markets, operating within the Pharma & Medical Biotechnology sector, specifically in Biomaterials & Tissue Engineering.
Strategic signal
In July 2023, Betalin Therapeutics announced significant progress in revolutionizing Type 1 diabetes treatment with its micro pancreas technology. This development signals a potential breakthrough in chronic disease management, offering investors and innovation teams a strong indication of the company's advanced clinical progress and its commitment to addressing a critical unmet medical need in the diabetes market.
Log in to access full profile ›Company Intelligence Q&A
- What is Betalin Therapeutics' primary focus?
- Betalin Therapeutics focuses on developing an alternative to insulin injections and glucose testing for diabetes patients through its proprietary Engineered Micro Pancreas (EMP) technology.
- When was Betalin Therapeutics founded and by whom?
- Betalin Therapeutics was founded in July 2015 by Shuki Joshua Hershcovich and Shay Hershcovich.
- What was a significant recent funding event for Betalin Therapeutics?
- In February 2024, Betalin Therapeutics secured an equity crowdfunding round led by.
- Has Betalin Therapeutics received any grants?
- Yes, in January 2021, Betalin Therapeutics received a grant from EU Horizon 2020. Another grant was received from EU Horizon 2020 in September 2020.
- What is the status of Betalin Therapeutics' product development?
- Betalin Therapeutics' Engineered Micro Pancreas (EMP) is currently in the clinical trial stage, with progress reported in July 2023 regarding its potential to revolutionize Type 1 diabetes treatment.